8-K filing — Turn Therapeutics Inc. (TTRX)
Filed: 2026-08-18 AccNo: 0001213900-26-091002 Size: 190 KB Item 3.02: Unregistered Sales of Equity Securities
Read original at edgarStocks · News reference
Turn Therapeutics Publishes Peer-Reviewed Research Of GX-03 In Life.
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7%
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 12:06 PM
- Checked
- Aug 20, 2026, 12:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Turn Therapeutics Q2 EPS $(0.20) Misses $(0.02) Estimate
Read original at benzingaWhy Is Turn Therapeutics Stock Trading Higher Today?
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.
Read original at benzinga